GeoVax Labs, Inc. (GOVX) stock
GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.71−0.33 (-16.42%)
Close on Nov 13, 2026Market cap $717.73KP/E –Yield –
GeoVax Labs ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
GeoVax Labs's ebitda for the twelve months ending Sep 30, 2026 was -$18.28M. For fiscal 2025 it was -$21.57M. The highest annual figure on record is -$2.05M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.57M | – |
| FY2024 | Dec 31, 2024 | -$25.05M | – |
| FY2023 | Dec 31, 2023 | -$26.67M | – |
| FY2022 | Dec 31, 2022 | -$13.97M | – |
| FY2021 | Dec 31, 2021 | -$18.71M | – |
| FY2020 | Dec 31, 2020 | -$2.80M | – |
| FY2019 | Dec 31, 2019 | -$2.36M | – |
| FY2018 | Dec 31, 2018 | -$2.54M | – |
| FY2017 | Dec 31, 2017 | -$2.15M | – |
| FY2016 | Dec 31, 2016 | -$3.24M | – |
| FY2015 | Dec 31, 2015 | -$2.67M | – |
| FY2014 | Dec 31, 2014 | -$2.67M | – |
| FY2013 | Dec 31, 2013 | -$2.21M | – |
| FY2012 | Dec 31, 2012 | -$2.05M | – |
| FY2011 | Dec 31, 2011 | -$2.24M | – |
| FY2010 | Dec 31, 2010 | -$2.65M | – |
| FY2009 | Dec 31, 2009 | -$3.23M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$4.17M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.73M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$440.36K | – |
| Q2 FY2020 | Jun 30, 2020 | -$442.07K | – |
| Q1 FY2020 | Mar 31, 2020 | -$594.31K | – |
| Q4 FY2019 | Dec 31, 2019 | -$588.41K | – |
| Q3 FY2019 | Sep 30, 2019 | -$424.04K | – |
| Q2 FY2019 | Jun 30, 2019 | -$652.04K | – |
| Q1 FY2019 | Mar 31, 2019 | -$699.65K | – |
| Q4 FY2018 | Dec 31, 2018 | -$629.41K | – |
| Q3 FY2018 | Sep 30, 2018 | -$662.38K | – |
| Q2 FY2018 | Jun 30, 2018 | -$633.18K | – |
| Q1 FY2018 | Mar 31, 2018 | -$617.94K | – |
| Q4 FY2017 | Dec 31, 2017 | -$509.89K | – |
| Q3 FY2017 | Sep 30, 2017 | -$583.45K | – |
| Q2 FY2017 | Jun 30, 2017 | -$511.25K | – |
| Q1 FY2017 | Mar 31, 2017 | -$541.83K | – |
| Q4 FY2016 | Dec 31, 2016 | -$928.61K | – |
See a number that looks wrong?